Influence of methotrexate on infliximab pharmacokinetics and pharmacodynamics in ankylosing spondylitis (Q35640448)

9 August 2017

title

Influence of methotrexate on infliximab pharmacokinetics and pharmacodynamics in ankylosing spondylitis (English)

1 reference

9 August 2017

1 reference

1 reference

1 reference

6

Daniel Wendling

1 reference

9 August 2017

David Ternant

1

1 reference

9 August 2017

Denis Mulleman

2

1 reference

9 August 2017

Francine Lauféron

3

1 reference

9 August 2017

Céline Vignault

4

1 reference

9 August 2017

Emilie Ducourau

5

1 reference

9 August 2017

Philippe Goupille

7

1 reference

9 August 2017

Gilles Paintaud

8

1 reference

9 August 2017

language of work or name

English

0 references

publication date

1 January 2012

1 reference

British Journal of Clinical Pharmacology

9 August 2017

published in

1 reference

9 August 2017

volume

73

1 reference

9 August 2017

issue

1

1 reference

9 August 2017

page(s)

55-65

1 reference

Population pharmacokinetic analysis of infliximab in patients with ulcerative colitis

9 August 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3248256

A systematic MEDLINE analysis of therapeutic approaches in ankylosing spondylitis

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3248256

Tumor burden influences exposure and response to rituximab: pharmacokinetic-pharmacodynamic modeling using a syngeneic bioluminescent murine model expressing human CD20.

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3248256

Population pharmacokinetics of infliximab in patients with ankylosing spondylitis

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3248256

Computing normalised prediction distribution errors to evaluate nonlinear mixed-effect models: the npde add-on package for R.

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3248256

Decreased clinical response to infliximab in ankylosing spondylitis is correlated with anti-infliximab formation

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3248256

The pharmacokinetics and pharmacodynamics of monoclonal antibodies--mechanistic modeling applied to drug development.

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3248256

Estimation of population pharmacokinetic parameters of saquinavir in HIV patients with the MONOLIX software

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3248256

A mechanism-based binding model for the population pharmacokinetics and pharmacodynamics of omalizumab.

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3248256

Methotrexate for ankylosing spondylitis

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3248256

Elimination mechanisms of therapeutic monoclonal antibodies

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3248256

Pharmacokinetics/pharmacodynamics of nondepleting anti-CD4 monoclonal antibody (TRX1) in healthy human volunteers

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3248256

Infliximab in combination with methotrexate in active ankylosing spondylitis: a clinical and imaging study

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3248256

Relationship between serum trough infliximab levels, pretreatment C reactive protein levels, and clinical response to infliximab treatment in patients with rheumatoid arthritis

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3248256

A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3248256

Withdrawal of immunosuppression in Crohn's disease treated with scheduled infliximab maintenance: a randomized trial

27 July 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2125.2011.04050.X

Clinical pharmacokinetics and use of infliximab

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2125.2011.04050.X

No efficacy of subcutaneous methotrexate in active ankylosing spondylitis: a 16-week open-label trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2125.2011.04050.X

Circulating concentration of infliximab and response to treatment in ankylosing spondylitis: results from a randomized control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2125.2011.04050.X

Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2125.2011.04050.X

An enzyme-linked immunosorbent assay for therapeutic drug monitoring of infliximab.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2125.2011.04050.X

Target-mediated drug disposition model: relationships with indirect response models and application to population PK-PD analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2125.2011.04050.X

Disease progression and pharmacodynamics in Parkinson disease - evidence for functional protection with levodopa and other treatments.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2125.2011.04050.X

Infliximab pharmacokinetics in inflammatory bowel disease patients.

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3248256

Influence of Immunogenicity on the Long-Term Efficacy of Infliximab in Crohn's Disease

25 September 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2125.2011.04050.X

Maintenance of infliximab treatment in ankylosing spondylitis: Results of a one-year randomized controlled trial comparing systematic versus on-demand treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2125.2011.04050.X

Trough infliximab concentration may predict long-term maintenance of infliximab in ankylosing spondylitis

21 January 2018

1 reference

12 December 2020

The relationship of serum infliximab concentrations to clinical improvement in rheumatoid arthritis: results from ATTRACT, a multicenter, randomized, double-blind, placebo-controlled trial

1 reference

12 December 2020

Serum cytokines (IL-6, TNF-alpha, IL-1 beta and IFN-gamma) in ankylosing spondylitis: a close correlation between serum IL-6 and disease activity and severity

1 reference

12 December 2020

Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis

1 reference

12 December 2020

Population pharmacokinetics of rituximab (anti-CD20 monoclonal antibody) in rheumatoid arthritis patients during a phase II clinical trial

1 reference

12 December 2020

Population pharmacokinetics of trastuzumab in patients with HER2+ metastatic breast cancer

1 reference

12 December 2020

Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial

1 reference

12 December 2020

A relationship between pharmacokinetics (PK) and the efficacy of infliximab for patients with rheumatoid arthritis: characterization of infliximab-resistant cases and PK-based modified therapy

1 reference

12 December 2020

Increased efficacy of infliximab associated with methotrexate in ankylosing spondylitis

1 reference

12 December 2020

10.1111/J.1365-2125.2011.04050.X

Identifiers

DOI

1 reference

9 August 2017

1 reference

9 August 2017

1 reference